News >

Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial

Jason M. Broderick @jasoncology
Published: Tuesday, Jan 16, 2018

Roger M. Perlmutter, MD, PhD

Roger M. Perlmutter, MD, PhD
Combining pembrolizumab (Keytruda) with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer (NSCLC), according to findings from the phase III KEYNOTE-189 trial. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication